Sort by 'likes'
Waldenstrom’s Macroglobulinemia: Advances in Treatments
Waldenstrom’s macroglobulinemia (WM) is a lymphoma, or cancer of the lymphatic system. The disease begins in a type of white blood cell called a B-lymphocyte, which normally matures into a plasma cell. In WM, there is a malignant change to…
Transforming Multiple Sclerosis Care Through Precision Medicine
Multiple sclerosis (MS) is a neurological condition where the immune system attacks the nerve fibers thereby affecting the functions of the brain and spinal cord. It affects about 2.8 million people worldwide and leads to symptoms that can vary from…
Post-Transplant Outcomes in High Risk Multiple Myeloma
Treatment of patients with myeloma has changed dramatically in the past years due to development of new agents and myeloma specific targets. Despite these advancements, long term benefits remains less clear in high-risk multiple myeloma patients. Myeloma is classified as…
What’s New in Multiple Myeloma Management?
Multiple myeloma is diagnosed in over 100,000 patients each year worldwide. The FDA recently granted accelerated approval to Teclistamab, the first bispecific B-cell maturation (BCMA)-directed CD3 T-cell engager. The therapeutic armamentarium for myeloma now includes alkylating agents, corticosteroids, deacetylase inhibitors,…
Myeloma: 2016 Year in Review and Outlook for 2017
The treatment options for myeloma continued to evolve in 2016 with new agents, immune based therapies and repurposing of existing approved agents. High-dose therapy and autologous stem cell transplantation remain the backbone of upfront treatment in myeloma. We are talking…